Highlights in this issue  by unknown
Highlights in this issue
What is the optimal sequence of imaging in neoadjuvant treatment of CRC
liver metastases?
In this issue of HPB, Sturesson et al report on 29 (16%) patients from a series of 179 who were assessed as having disappearing
colorectal liver metastases (DLM) following the administration of neoadjuvant chemotherapy. In these patients, 66 DLM were
identified preoperatively and 42 (64%) of these were identified at surgery and treated. Of the 24 tumours that were not identi-
fied four were potentially left in situ. One of these four lesions subsequently recurred although the follow up period was not
provided. Contrast enhanced ultrasound (US) only detected one lesion that was not identified by intraoperative palpation,
inspection, or conventional radiologist led US. It was perhaps not unexpected that both MRI and CT performed poorly in
radiological reassessment after chemotherapy for lesions less than 10 mm in size. Although the sensitivity of MRI would appear
to be greater than CT, intraoperative assessment was clearly better. Definitions, radiological methodology and chemotherapeu-
tic options are all important considerations to be taken into account in this field. The authors correctly highlight the study
deficiencies including the lack of use of diffusion weighted imaging and the inconsistent use of pre chemotherapy MRI. Despite
these limitations the messages are clear. Prior to chemotherapy optimal imaging is required in the form of MRI with hepatic
specific agents. Recognise that DLM are more likely to occur in patients with small lesions. Post chemotherapy radiological
assessment is limited in detecting progression within the liver but can be determined by contrast enhanced CT. Intraoperatively
one should plan to resect all disease identified prior to chemotherapy with intraoperative US being performed by those experi-
enced in its use. In the event of undetected DLM, patients should be followed up. It may also be useful to consider whether a
flexible approach may be indicated for those with complicated disease. For example, for bilobar disease with small lesions deep
within the future liver remnant (FLR), would upfront ablation of lesions within the FLR followed by chemotherapy and
subsequent resection reduce the chance of creating a scenario of untreated DLM in a FLR stimulated by growth factors?
Saxon Connor
Should we resect giant hepatocellular carcinomas?
Giant hepatocellular carcinomas (GHCC) defined as having a diameter >10 cm are thankfully relatively uncommon.
Liver surgeons will be familiar with the presentation of patients with large tumours but little, if any, symptoms and
the management options for such patients can be limited.
In this issue of HPB, Thng and colleagues from Singapore present their experience with resecting 23 GHCC and
compare them with patients undergoing resection for smaller HCC. In this study almost three quarters of patients
were aware of an abdominal mass but only a quarter complained of pain. They found that patients presenting with
resectable GHCC were more likely to have well preserved liver function than those with small HCC, although we do
not know how many patients with GHCC were found to be nonresectable based on their liver function. Resection was
perhaps not surprisingly more likely to require an open approach and a significant number required an anterior
approach because of difficulty in safely mobilizing the right lobe of the liver. Histological data showed that half the
tumours demonstrated microvascular invasion and 40% showed lymphatic invasion. The incidence of satellite lesions
was the same as for small HCC. Margin involvement occurred in 13% of patients compared with 2% in small HCC.
On multivariate analysis the presence of satellite lesions and the requirement for perioperative blood transfusion
were associated with a poor overall survival outcome but these factors affected patients with both small and GHCC.
The overall outcome of patients with GHCC was not significantly different from those with small HCC although this
may be a consequence of the relatively small number of patients in the study. Notwithstanding this limitation 50% of
patients undergoing resection for GHCC survived at least 3 years. This study shows that if patients have adequate liver
function and can tolerate resection then surgery for GHCC is certainly advantageous.
Stephen J. Wigmore
Tracking yet another route of escape
Because extended lymphadenectomy (LA) during pancreaticoduodenectomy (PD) for peri-ampullary cancer does not
improve oncologic outcomes, a lesser standard LA (S-LA) has been recommended. It does not include deliberate resection of
those nodes behind the pancreatic head between the aorta and inferior vena cava (station 16). Should these nodes be removed,
and if so why? For extending survival? For better staging? For an intraoperative hard-stop biopsy as to the futility of PD?
Nappo et al from Professor Coppola’s unit in Rome prospectively evaluated 135 consecutive patients whose PD for peri-am-
pullary cancer did include resection of these para-aortic lymph nodes (PALN). The incidence of PALN metastases (N16+) was
over 11%, not surprising given the known lymphatic drainage pathways for the pancreatic head. This incidence apparently
mirrors that for other nodes resected during S-LA. When N16+ for these patients, survival was no better or worse than for all
other N1 patients collectively identified. The authors believe this should support continuing with resection, and not abandon-
ing upon a N16+ frozen section. After all, so many patients are ultimately identified on final pathology as being N1. Further,
why not N16? Sampling seems easy enough to do as indicated by the authors (16a2, 16b1). But, as also discussed thoroughly
by the authors, the oncologic and prognostic implications of N16+ status are difficult to clarify, and what literature we have is
discordant. Some studies say stop, the PD will be futile. Others and now Nappo et al support sampling N16 PALN and even if
positive to press on with PD. I remain content being agnostic to N16 status. After all, isn’t it the rare patient with peri-am-
pullary cancer that will be N0 for S-LA but have isolated positive PALN? Most likely. the objective of PD for cancer comes
down to local control. If the enemy has escaped, we know S-LA is sufficient staging for the majority of patients. Perhaps the
true prognostic utility of N16+ status lies in pre-operative staging (i.e. EUS-FNA) well before an invasive operation has begun.
Mark Callery
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